Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 580
Filter
1.
Eur Neuropsychopharmacol ; 85: 10-20, 2024 Aug.
Article in English | MEDLINE | ID: mdl-38648694

ABSTRACT

Psychedelics like LSD (Lysergic acid diethylamide) and psilocybin are known to modulate perceptual modalities due to the activation of mostly serotonin receptors in specific cortical (e.g., visual cortex) and subcortical (e.g., thalamus) regions of the brain. In the visual domain, these psychedelic modulations often result in peculiar disturbances of viewed objects and light and sometimes even in hallucinations of non-existent environments, objects, and creatures. Although the underlying processes are poorly understood, research conducted over the past twenty years on the subjective experience of psychedelics details theories that attempt to explain these perceptual alterations due to a disruption of communication between cortical and subcortical regions. However, rare medical conditions in the visual system like Charles Bonnet syndrome that cause perceptual distortions may shed new light on the additional importance of the retinofugal pathway in psychedelic subjective experiences. Interneurons in the retina called amacrine cells could be the first site of visual psychedelic modulation and aid in disrupting the hierarchical structure of how humans perceive visual information. This paper presents an understanding of how the retinofugal pathway communicates and modulates visual information in psychedelic and clinical conditions. Therefore, we elucidate a new theory of psychedelic modulation in the retinofugal pathway.


Subject(s)
Hallucinations , Hallucinogens , Visual Pathways , Humans , Hallucinogens/pharmacology , Hallucinations/chemically induced , Hallucinations/physiopathology , Visual Pathways/drug effects , Lysergic Acid Diethylamide/pharmacology , Charles Bonnet Syndrome , Animals
2.
Cells ; 10(11)2021 11 16.
Article in English | MEDLINE | ID: mdl-34831417

ABSTRACT

Wolfram syndrome (WS), also known as a DIDMOAD (diabetes insipidus, early-onset diabetes mellitus, optic nerve atrophy and deafness) is a rare autosomal disorder caused by mutations in the Wolframin1 (WFS1) gene. Previous studies have revealed that glucagon-like peptide-1 receptor agonist (GLP1 RA) are effective in delaying and restoring blood glucose control in WS animal models and patients. The GLP1 RA liraglutide has also been shown to have neuroprotective properties in aged WS rats. WS is an early-onset, chronic condition. Therefore, early diagnosis and lifelong pharmacological treatment is the best solution to control disease progression. Hence, the aim of this study was to evaluate the efficacy of the long-term liraglutide treatment on the progression of WS symptoms. For this purpose, 2-month-old WS rats were treated with liraglutide up to the age of 18 months and changes in diabetes markers, visual acuity, and hearing sensitivity were monitored over the course of the treatment period. We found that treatment with liraglutide delayed the onset of diabetes and protected against vision loss in a rat model of WS. Therefore, early diagnosis and prophylactic treatment with the liraglutide may also prove to be a promising treatment option for WS patients by increasing the quality of life.


Subject(s)
Diabetes Mellitus, Experimental/drug therapy , Glucagon-Like Peptide-1 Receptor/agonists , Hearing Loss, Sensorineural/drug therapy , Liraglutide/therapeutic use , Nerve Degeneration/drug therapy , Visual Pathways/pathology , Wolfram Syndrome/drug therapy , Animals , C-Peptide/metabolism , Diabetes Mellitus, Experimental/complications , Disease Models, Animal , Glucagon-Like Peptide-1 Receptor/metabolism , Hearing Loss, Sensorineural/complications , Liraglutide/pharmacology , Male , Nerve Degeneration/complications , Optic Nerve/drug effects , Optic Nerve/pathology , Optic Nerve/ultrastructure , Phenotype , Rats , Visual Pathways/drug effects , Wolfram Syndrome/complications
3.
Front Neural Circuits ; 15: 662349, 2021.
Article in English | MEDLINE | ID: mdl-34305536

ABSTRACT

Our sensory systems such as the olfactory and visual systems are the target of neuromodulatory regulation. This neuromodulation starts at the level of sensory receptors and extends into cortical processing. A relatively new group of neuromodulators includes cannabinoids. These form a group of chemical substances that are found in the cannabis plant. Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) are the main cannabinoids. THC acts in the brain and nervous system like the chemical substances that our body produces, the endogenous cannabinoids or endocannabinoids, also nicknamed the brain's own cannabis. While the function of the endocannabinoid system is understood fairly well in limbic structures such as the hippocampus and the amygdala, this signaling system is less well understood in the olfactory pathway and the visual system. Here, we describe and compare endocannabinoids as signaling molecules in the early processing centers of the olfactory and visual system, the olfactory bulb, and the retina, and the relevance of the endocannabinoid system for synaptic plasticity.


Subject(s)
Cannabinoids/metabolism , Neuronal Plasticity/physiology , Olfactory Bulb/metabolism , Smell/physiology , Visual Pathways/metabolism , Visual Perception/physiology , Animals , Cannabinoids/administration & dosage , Humans , Neuronal Plasticity/drug effects , Olfactory Bulb/drug effects , Receptor, Cannabinoid, CB1/agonists , Receptor, Cannabinoid, CB1/metabolism , Retina/drug effects , Retina/metabolism , Smell/drug effects , Visual Pathways/drug effects , Visual Perception/drug effects
4.
J Neurol Neurosurg Psychiatry ; 92(12): 1319-1324, 2021 12.
Article in English | MEDLINE | ID: mdl-34187865

ABSTRACT

OBJECTIVE: To investigate potential neuroprotective and pro-remyelinating effects of alemtuzumab in multiple sclerosis (MS), using the visual pathway as a model. METHODS: We monitored clinical, multifocal visual evoked potential (mfVEP) and MRI outcomes in 30 patients commencing alemtuzumab for relapsing MS, and a reference group of 20 healthy controls (HCs), over 24 months. Change in mfVEP latency was the primary endpoint; change in optic radiation (OR) lesion diffusion metrics and Mars letter contrast sensitivity over the course of the study were secondary endpoints. RESULTS: In patients, we observed a mean shortening of mfVEP latency of 1.21 ms over the course of the study (95% CI 0.21 to 2.21, p=0.013), not altered by correction for age, gender, disease duration or change in OR T2 lesion volume. Mean mfVEP latency in the HC group increased over the course of the study by 0.72 ms (not significant). Analysis of chronic OR T2 lesions (patients) showed an increase in normalised fractional anisotropy and axial diffusivity between baseline and 24 months (both p<0.01). Mean Mars letter contrast sensitivity was improved at 24 months vs baseline (p<0.001), and driven by an early improvement, in both patients and HC. CONCLUSION: We found evidence of partial lesion remyelination after alemtuzumab therapy, indicating either natural restoration in the context of a 'permissive' local milieu; or potentially an independent, pro-reparative mechanism of action. The visual system presents a unique opportunity to study function-structure specific effects of therapy and inform the design of future phase 2 MS remyelination trials.


Subject(s)
Alemtuzumab/therapeutic use , Brain/diagnostic imaging , Evoked Potentials, Visual/physiology , Immunologic Factors/therapeutic use , Multiple Sclerosis/diagnostic imaging , Visual Pathways/diagnostic imaging , Adult , Alemtuzumab/pharmacology , Brain/drug effects , Evoked Potentials, Visual/drug effects , Female , Humans , Immunologic Factors/pharmacology , Magnetic Resonance Imaging , Male , Middle Aged , Multiple Sclerosis/drug therapy , Neurologic Examination , Visual Pathways/drug effects , Young Adult
5.
Neurotherapeutics ; 18(2): 1339-1359, 2021 04.
Article in English | MEDLINE | ID: mdl-33846961

ABSTRACT

Glaucoma is a neurodegenerative disease that causes progressive, irreversible vision loss. Currently, intraocular pressure (IOP) is the only modifiable risk factor for glaucoma. However, glaucomatous degeneration may continue despite adequate IOP control. Therefore, there exists a need for treatment that protects the visual system, independent of IOP. This study sought, first, to longitudinally examine the neurobehavioral effects of different magnitudes and durations of IOP elevation using multi-parametric magnetic resonance imaging (MRI), optokinetics and histology; and, second, to evaluate the effects of oral citicoline treatment as a neurotherapeutic in experimental glaucoma. Eighty-two adult Long Evans rats were divided into six groups: acute (mild or severe) IOP elevation, chronic (citicoline-treated or untreated) IOP elevation, and sham (acute or chronic) controls. We found that increasing magnitudes and durations of IOP elevation differentially altered structural and functional brain connectivity and visuomotor behavior, as indicated by decreases in fractional anisotropy in diffusion tensor MRI, magnetization transfer ratios in magnetization transfer MRI, T1-weighted MRI enhancement of anterograde manganese transport, resting-state functional connectivity, visual acuity, and neurofilament and myelin staining along the visual pathway. Furthermore, 3 weeks of oral citicoline treatment in the setting of chronic IOP elevation significantly reduced visual brain integrity loss and visual acuity decline without altering IOP. Such effects sustained after treatment was discontinued for another 3 weeks. These results not only illuminate the close interplay between eye, brain, and behavior in glaucomatous neurodegeneration, but also support a role for citicoline in protecting neural tissues and visual function in glaucoma beyond IOP control.


Subject(s)
Cytidine Diphosphate Choline/pharmacology , Intraocular Pressure/drug effects , Nootropic Agents/pharmacology , Optic Nerve/drug effects , Visual Pathways/drug effects , Animals , Behavior, Animal/drug effects , Diffusion Tensor Imaging , Eye Movement Measurements , Female , Glaucoma , Multiparametric Magnetic Resonance Imaging , Neural Pathways/drug effects , Neurodegenerative Diseases/physiopathology , Ocular Hypertension/physiopathology , Optic Nerve/diagnostic imaging , Optic Nerve/pathology , Proton Magnetic Resonance Spectroscopy , Psychomotor Performance/drug effects , Rats , Severity of Illness Index , Time Factors , Visual Acuity/drug effects , Visual Pathways/diagnostic imaging , Visual Pathways/pathology
6.
Int J Mol Sci ; 22(4)2021 Feb 09.
Article in English | MEDLINE | ID: mdl-33572198

ABSTRACT

Post-traumatic stress disorder (PTSD) has a high lifetime prevalence and is one of the more serious challenges in mental health care. Fear-conditioned learning involving the amygdala has been thought to be one of the main causative factors; however, recent studies have reported abnormalities in the thalamus of PTSD patients, which may explain the mechanism of interventions such as eye movement desensitization and reprocessing (EMDR). Therefore, I conducted a miniature literature review on the potential contribution of the thalamus to the pathogenesis of PTSD and the validation of therapeutic approaches. As a result, we noticed the importance of the retinotectal pathway (superior colliculus-pulvinar-amygdala connection) and discussed therapeutic indicators.


Subject(s)
Amygdala/physiopathology , Pulvinar/physiopathology , Retina/physiopathology , Stress Disorders, Post-Traumatic/physiopathology , Superior Colliculi/physiopathology , Amygdala/diagnostic imaging , Animals , Conditioning, Psychological/drug effects , Conditioning, Psychological/physiology , Connectome/methods , Diffusion Tensor Imaging , Disease Models, Animal , Eye Movement Desensitization Reprocessing/methods , Fear/physiology , Fear/psychology , Humans , Hyperbaric Oxygenation , Oxytocin/administration & dosage , Pulvinar/diagnostic imaging , Retina/diagnostic imaging , Stress Disorders, Post-Traumatic/diagnosis , Stress Disorders, Post-Traumatic/psychology , Stress Disorders, Post-Traumatic/therapy , Superior Colliculi/diagnostic imaging , Treatment Outcome , Visual Pathways/diagnostic imaging , Visual Pathways/drug effects , Visual Pathways/physiopathology
7.
Neuroimage ; 226: 117542, 2021 02 01.
Article in English | MEDLINE | ID: mdl-33186719

ABSTRACT

The functional characteristics of the mouse visual system have not previously been well explored using fMRI. In this research, we examined 9.4 T BOLD fMRI responses to visual stimuli of varying pulse durations (1 - 50 ms) and temporal frequencies (1 - 10 Hz) under ketamine and xylazine anesthesia, and compared fMRI responses of anesthetized and awake mice. Under anesthesia, significant positive BOLD responses were detected bilaterally in the major structures of the visual pathways, including the dorsal lateral geniculate nuclei, superior colliculus, lateral posterior nucleus of thalamus, primary visual area, and higher-order visual area. BOLD responses increased slightly with pulse duration, were maximal at 3 - 5 Hz stimulation, and significantly decreased at 10 Hz, which were all consistent with previous neurophysiological findings. When the mice were awake, the BOLD fMRI response was faster in all active regions and stronger in the subcortical areas compared with the anesthesia condition. In the V1, the BOLD response was biphasic for 5 Hz stimulation and negative for 10 Hz stimulation under wakefulness, whereas prolonged positive BOLD responses were observed at both frequencies under anesthesia. Unexpected activation was detected in the extrastriate postrhinal area and non-visual subiculum complex under anesthesia, but not under wakefulness. Widespread positive BOLD activity under anesthesia likely results from the disinhibition and sensitization of excitatory neurons induced by ketamine. Overall, fMRI can be a viable tool for mapping brain-wide functional networks.


Subject(s)
Anesthetics, Dissociative/pharmacology , Brain/diagnostic imaging , Ketamine/pharmacology , Visual Pathways/diagnostic imaging , Wakefulness/physiology , Anesthesia , Animals , Brain/drug effects , Magnetic Resonance Imaging , Male , Mice , Photic Stimulation , Visual Cortex/diagnostic imaging , Visual Cortex/drug effects , Visual Pathways/drug effects
8.
Brain Pathol ; 31(2): 312-332, 2021 03.
Article in English | MEDLINE | ID: mdl-33368801

ABSTRACT

Visual deficits are among the most prevalent symptoms in patients with multiple sclerosis (MS). To understand deficits in the visual pathway during MS and potential treatment effects, we used experimental autoimmune encephalomyelitis (EAE), the most commonly used animal model of MS. The afferent visual pathway was assessed in vivo using optical coherence tomography (OCT), electroretinography (ERG), and visually evoked cortical potentials (VEPs). Inflammation, demyelination, and neurodegeneration were examined by immunohistochemistry ex vivo. In addition, an immunomodulatory, remyelinating agent, the estrogen receptor ß ligand chloroindazole (IndCl), was tested for its therapeutic potential in the visual pathway. EAE produced functional deficits in visual system electrophysiology, including suppression of ERG and VEP waveform amplitudes and increased signal latencies. Therapeutic IndCl rescued overall visual system latency by VEP but had little impact on amplitude or ERG findings relative to vehicle. Faster VEP conduction in IndCl-treated mice was associated with enhanced myelin basic protein signal in all visual system structures examined. IndCl preserved retinal ganglion cells (RGCs) and oligodendrocyte density in the prechiasmatic white matter, but similar retinal nerve fiber layer thinning by OCT was noted in vehicle and IndCl-treated mice. Although IndCl differentially attenuated leukocyte and astrocyte staining signal throughout the structures analyzed, axolemmal varicosities were observed in all visual fiber tracts of mice with EAE irrespective of treatment, suggesting impaired axonal energy homeostasis. These data support incomplete functional recovery of VEP amplitude with IndCl, as fiber tracts displayed persistent axon pathology despite remyelination-induced decreases in latencies, evidenced by reduced optic nerve g-ratio in IndCl-treated mice. Although additional studies are required, these findings demonstrate the dynamics of visual pathway dysfunction and disability during EAE, along with the importance of early treatment to mitigate EAE-induced axon damage.


Subject(s)
Azo Compounds/pharmacology , Encephalomyelitis, Autoimmune, Experimental/pathology , Naphthalenes/pharmacology , Remyelination/drug effects , Visual Pathways/drug effects , Visual Pathways/pathology , Animals , Evoked Potentials, Visual/drug effects , Inflammation/pathology , Mice , Mice, Inbred C57BL , Multiple Sclerosis , Nerve Degeneration/pathology
9.
Brain Res Bull ; 164: 392-399, 2020 11.
Article in English | MEDLINE | ID: mdl-32926949

ABSTRACT

Our recent report demonstrated that hesperetin (Hst) as a citrus flavonoid, significantly reduces the levels of demyelination in optic chiasm of rats. Previous evidence also indicated that nano-hesperetin (nano-Hst) possesses beneficial impacts in experimental models of Alzheimer's disease and autism. In this study, the effects of nano-Hst on latency of visual signals, demyelination levels, glial activation, and expression of Olig2 and MBP were evaluated in lysolecithin (LPC)-induced demyelination model. Focal demyelination was induced by injection of LPC (1%, 2 µL) into the rat optic chiasm. Animals received oral administration of nano-Hst at dose of 20 mg/kg for 14 or 21 days post LPC injection. Visual evoked potential (VEP) recording showed that nano-Hst reduces the latency of visual signals and ameliorates the extent of demyelination areas and glial activation. Expression levels of the Olig2 and MBP were also significantly increased in nano-Hst treated rats. Overall, our data suggest that nano-Hst reduces the latency of visual signals through its protective effects on myelin sheath, amelioration of glial activation, and enhancement of endogenous remyelination.


Subject(s)
Demyelinating Diseases/drug therapy , Hesperidin/pharmacology , Optic Chiasm/drug effects , Recovery of Function/drug effects , Remyelination/drug effects , Visual Pathways/drug effects , Animals , Demyelinating Diseases/physiopathology , Disease Models, Animal , Evoked Potentials, Visual/drug effects , Evoked Potentials, Visual/physiology , Hesperidin/therapeutic use , Male , Optic Chiasm/physiopathology , Rats , Rats, Wistar , Visual Cortex/drug effects , Visual Cortex/physiopathology , Visual Pathways/physiopathology
10.
Epilepsy Res ; 166: 106395, 2020 10.
Article in English | MEDLINE | ID: mdl-32679486

ABSTRACT

Vigabatrin (VGB; γ-vinyl-GABA) is an antiepileptic drug that elevates CNS GABA via irreversible inactivation of the GABA catabolic enzyme GABA-transaminase. VGB's clinical utility, however, can be curtailed by peripheral visual field constriction (pVFC) and thinning of the retinal nerve fiber layer (RNFL). Earlier studies from our laboratory revealed disruptions of autophagy by VGB. Here, we tested the hypothesis that VGB administration to animals would reveal alterations of gene expression in VGB-treated retina that associated with autophagy. VGB (140 mg/kg/d; subcutaneous minipump) was continuously administered to mice (n = 6 each VGB/vehicle) for 12 days, after which animals were euthanized. Retina was isolated for transcriptome (RNAseq) analysis and further validation using qRT-PCR and immunohistochemistry (IHC). For 112 differentially expressed retinal genes (RNAseq), two databases (Gene Ontology; Kyoto Encyclopedia of Genes and Genomes) were used to identify genes associated with visual function. Twenty four genes were subjected to qRT-PCR validation, and five (Gb5, Bdnf, Cplx9, Crh, Sox9) revealed significant dysregulation. IHC of fixed retinas verified significant down-regulation of Gb5 in photoreceptor cells. All of these genes have been previously shown to play a role in retinal function/circuitry signaling. Minimal impact of VGB on retinal autophagic gene expression was observed. This is the first transcriptome analysis of retinal gene expression associated with VGB intake, highlighting potential novel molecular targets potentially related to VGB's well known ocular toxicity.


Subject(s)
Anticonvulsants/pharmacology , Gene Expression Profiling/methods , Nerve Net/physiology , Retina/physiology , Vigabatrin/pharmacology , Visual Pathways/physiology , Animals , Male , Mice , Mice, Inbred C57BL , Nerve Net/chemistry , Nerve Net/drug effects , Retina/chemistry , Retina/drug effects , Sequence Analysis, RNA/methods , Visual Pathways/chemistry , Visual Pathways/drug effects
11.
Int J Mol Sci ; 21(5)2020 Feb 25.
Article in English | MEDLINE | ID: mdl-32106602

ABSTRACT

Combined administration of N-Methyl-D-Aspartate (NMDA) and kainic acid (KA) on the inner retina was studied as a model of excitotoxicity. The right eye of C57BL6J mice was injected with 1 µL of PBS containing NMDA 30 mM and KA 10 mM. Only PBS was injected in the left eye. One week after intraocular injection, electroretinogram recordings and immunohistochemistry were performed on both eyes. Retinal ganglion cell (RGC) projections were studied by fluorescent-cholerotoxin anterograde labeling. A clear decrease of the retinal "b" wave amplitude, both in scotopic and photopic conditions, was observed in the eyes injected with NMDA/KA. No significant effect on the "a" wave amplitude was observed, indicating the preservation of photoreceptors. Immunocytochemical labeling showed no effects on the outer nuclear layer, but a significant thinning on the inner retinal layers, thus indicating that NMDA and KA induce a deleterious effect on bipolar, amacrine and ganglion cells. Anterograde tracing of the visual pathway after NMDA and KA injection showed the absence of RGC projections to the contralateral superior colliculus and lateral geniculate nucleus. We conclude that glutamate receptor agonists, NMDA and KA, induce a deleterious effect of the inner retina when injected together into the vitreous chamber.


Subject(s)
Amacrine Cells/drug effects , Excitatory Amino Acid Agonists/toxicity , Kainic Acid/toxicity , N-Methylaspartate/toxicity , Photoreceptor Cells/drug effects , Retinal Ganglion Cells/drug effects , Amacrine Cells/pathology , Amacrine Cells/physiology , Animals , Cells, Cultured , Membrane Potentials , Mice , Mice, Inbred C57BL , Photoreceptor Cells/pathology , Photoreceptor Cells/physiology , Retinal Ganglion Cells/pathology , Retinal Ganglion Cells/physiology , Visual Pathways/drug effects , Visual Pathways/pathology , Visual Pathways/physiology
12.
Brain Res Bull ; 157: 1-9, 2020 04.
Article in English | MEDLINE | ID: mdl-31982453

ABSTRACT

Contrast sensitivity (CS) is one of the primary fundamental factors determining how well we can see, and it directly influences object recognition. Whether bisphenol-A (BPA, an environmental xenoestrogen) can perturb contrast detection in the visual system has yet to be elucidated. In the present study, we analyzed CS of single neurons in the primary visual cortex (area 17, A17) of cats before and after BPA exposure using a multiple-channel recording technique. The results showed that CS of A17 neurons was markedly depressed with an increased contrast threshold after two hour of intravenous BPA administration, which had a positive correlation with decreased firing rates of A17 neurons. Additionally, responses of these neurons presented an overt increase in the trial-to-trail response variability (a kind of neuronal noise), which could disturb the information-filtering function of single neurons. We also found that neuronal CS in the visual relay station was not disturbed after BPA administration, which rules out the contribution of CS alteration in the optical pathway. Importantly, acute BPA treatment obviously increased the inhibitory innervation to the visual pyramidal neurons. This implies that alteration of intracortical inhibitory regulation contributes to the compromised contrast detection in the visual system after BPA treatment.


Subject(s)
Benzhydryl Compounds/pharmacology , Noise , Phenols/pharmacology , Synaptic Transmission/physiology , Visual Pathways/drug effects , Visual Perception/drug effects , Animals , Cats , Contrast Sensitivity/drug effects , Neurons/drug effects , Neurons/physiology , Photic Stimulation/methods , Pyramidal Cells/drug effects , Visual Cortex/physiology
14.
Neuron ; 102(2): 493-505.e5, 2019 04 17.
Article in English | MEDLINE | ID: mdl-30878289

ABSTRACT

Extensive research suggests that the inferior temporal (IT) population supports visual object recognition behavior. However, causal evidence for this hypothesis has been equivocal, particularly beyond the specific case of face-selective subregions of IT. Here, we directly tested this hypothesis by pharmacologically inactivating individual, millimeter-scale subregions of IT while monkeys performed several core object recognition subtasks, interleaved trial-by trial. First, we observed that IT inactivation resulted in reliable contralateral-biased subtask-selective behavioral deficits. Moreover, inactivating different IT subregions resulted in different patterns of subtask deficits, predicted by each subregion's neuronal object discriminability. Finally, the similarity between different inactivation effects was tightly related to the anatomical distance between corresponding inactivation sites. Taken together, these results provide direct evidence that the IT cortex causally supports general core object recognition and that the underlying IT coding dimensions are topographically organized.


Subject(s)
Pattern Recognition, Visual/physiology , Temporal Lobe/physiology , Visual Pathways/physiology , Animals , Behavior, Animal , Brain Mapping , GABA-A Receptor Agonists/pharmacology , Macaca mulatta , Male , Muscimol/pharmacology , Neurons/drug effects , Neurons/physiology , Pattern Recognition, Visual/drug effects , Temporal Lobe/drug effects , Visual Pathways/drug effects
15.
Adv Ther ; 36(4): 987-996, 2019 04.
Article in English | MEDLINE | ID: mdl-30790180

ABSTRACT

INTRODUCTION: To evaluate the retinal function and the relative neural conduction along the visual pathway after treatment with citicoline in liposomal formulation (CLF) eye drops in patients with open angle glaucoma (OAG). METHODS: Twelve OAG patients (mean age ± standard deviation 52.58 ± 11.39 years, intraocular pressure < 18 mmHg under topical hypotensive treatment, Humphrey field analyzer mean deviation - 4.49 ± 2.46 dB) were enrolled. Only one eye of studied patients was treated with CLF eye drops (OMK1-LF®, Omikron Italia, 3 drops/day) (CLF group, 12 eyes) over a period of 4 months. In CLF eyes, pattern electroretinogram (PERG), visual evoked potentials (VEP), and visual field test were assessed at baseline and at the end of treatment (month 4). RESULTS: After treatment with CLF eye drops, a significant increase of PERG P50-N95 amplitude and a significant shortening of VEP P100 implicit time were found. In CLF eyes, the shortening of VEP P100 implicit time was significantly correlated with the increase of PERG P50-N95 amplitude. CONCLUSION: Data from this pilot study suggest that treatment with CLF eye drops induces an enhancement of the retinal bioelectrical responses (increase of PERG amplitude) with a consequent improvement of the bioelectrical activity of the visual cortex (shortening of VEP implicit time). FUNDING: Omikron Italia S.r.l. and Opko Health Europe.


Subject(s)
Cytidine Diphosphate Choline , Evoked Potentials, Visual , Glaucoma, Open-Angle , Biological Availability , Cytidine Diphosphate Choline/administration & dosage , Cytidine Diphosphate Choline/pharmacokinetics , Drug Monitoring , Electroretinography/methods , Female , Glaucoma, Open-Angle/diagnosis , Glaucoma, Open-Angle/drug therapy , Humans , Liposomes , Male , Middle Aged , Neural Conduction/drug effects , Ophthalmic Solutions/administration & dosage , Ophthalmic Solutions/pharmacokinetics , Pilot Projects , Retina/drug effects , Retina/physiopathology , Tonometry, Ocular/methods , Visual Field Tests/methods , Visual Pathways/drug effects
16.
Neurosci Lett ; 698: 7-12, 2019 04 17.
Article in English | MEDLINE | ID: mdl-30611891

ABSTRACT

Interleukin-6 (IL-6) is involved in different processes of the central nervous system. Our aims were to investigate the effect of IL-6 on retinotectal topography and on different signaling pathways. Rats were submitted to an intravitreous injection of either IL-6 (50 ng/ml) or PBS (vehicle) at postnatal day 10 (PND10). At PND11 or PND14, different groups were processed for western blot, histochemistry or immunofluorescence analysis. IL-6 treatment leads to an increase in pSTAT-3 levels in the retina and a disruption in the retinotectal topographic map, suggesting that a transient increase in interleukin-6 levels may impact neural circuitry development.


Subject(s)
Interleukin-6/pharmacology , Visual Pathways/growth & development , Animals , Interleukin-6/administration & dosage , Interleukin-6/physiology , Intravitreal Injections , Phosphorylation , Rats , Retina/drug effects , Retina/growth & development , Retina/metabolism , STAT3 Transcription Factor/metabolism , Signal Transduction , Superior Colliculi/drug effects , Superior Colliculi/growth & development , Superior Colliculi/physiology , Visual Pathways/drug effects , Visual Pathways/physiology
17.
Eur J Neurosci ; 50(1): 1712-1726, 2019 07.
Article in English | MEDLINE | ID: mdl-30687960

ABSTRACT

Glucocorticoid hormones and serotonin (5-HT) are strongly associated with the development and treatment of depression, respectively. Glucocorticoids regulate the function of serotonergic neurons in the dorsal raphe nucleus (DR), which are the major source of 5-HT to the forebrain. DR 5-HT neurons are electrophysiologically heterogeneous, though whether this phenotypic variation aligns with specific brain functions or neuropsychiatric disease states is largely unknown. The goal of this work was to determine if chronic exogenous glucocorticoid administration differentially affects the electrophysiological profile of DR neurons implicated in the regulation of emotion versus visual sensation by comparing properties of cells projecting to medial prefrontal cortex (mPFC) versus lateral geniculate nucleus (LGN). Following retrograde tracer injection into mPFC or LGN, male Sprague-Dawley rats received daily injections of corticosterone (CORT) for 21 days, after which whole-cell patch clamp recordings were made from retrogradely labeled DR neurons. CORT-treatment significantly increased the action potential half-width of LGN-projecting DR neurons, but did not significantly affect the firing frequency or excitatory postsynaptic currents of these cells. CORT-treatment significantly reduced the input resistance, evoked firing frequency, and spontaneous excitatory postsynaptic current frequency of mPFC-projecting DR neurons, indicating a concurrent reduction of both intrinsic excitability and excitatory drive. Our results suggest that the serotonergic regulation of cognitive and emotional networks in the mPFC may be more sensitive to the effects of glucocorticoid excess than visual sensory circuits in the LGN and that reduced 5-HT transmission in the mPFC may underlie the association between glucocorticoid excess and depression.


Subject(s)
Corticosterone/pharmacology , Dorsal Raphe Nucleus/metabolism , Excitatory Postsynaptic Potentials/physiology , Geniculate Bodies/metabolism , Glucocorticoids/metabolism , Nerve Net/metabolism , Prefrontal Cortex/metabolism , Serotonergic Neurons/metabolism , Serotonin/metabolism , Visual Pathways/metabolism , Animals , Corticosterone/administration & dosage , Depression/metabolism , Dorsal Raphe Nucleus/drug effects , Excitatory Postsynaptic Potentials/drug effects , Geniculate Bodies/drug effects , Male , Nerve Net/drug effects , Neuroanatomical Tract-Tracing Techniques , Patch-Clamp Techniques , Prefrontal Cortex/drug effects , Rats , Rats, Sprague-Dawley , Serotonergic Neurons/drug effects , Visual Pathways/drug effects
18.
Nat Commun ; 9(1): 3895, 2018 09 25.
Article in English | MEDLINE | ID: mdl-30254324

ABSTRACT

The largest targets of retinal input in mammals are the dorsal lateral geniculate nucleus (dLGN), a relay to the primary visual cortex (V1), and the superior colliculus. V1 innervates and influences the superior colliculus. Here, we find that, in turn, superior colliculus modulates responses in mouse V1. Optogenetically inhibiting the superior colliculus reduces responses in V1 to optimally sized stimuli. Superior colliculus could influence V1 via its strong projection to the lateral posterior nucleus (LP/Pulvinar) or its weaker projection to the dLGN. Inhibiting superior colliculus strongly reduces activity in LP. Pharmacologically silencing LP itself, however, does not remove collicular modulation of V1. The modulation is instead due to a collicular gain modulation of the dLGN. Surround suppression operating in V1 explains the different effects for differently sized stimuli. Computations of visual saliency in the superior colliculus can thus influence tuning in the visual cortex via a tectogeniculate pathway.


Subject(s)
Geniculate Bodies/physiology , Pulvinar/physiology , Superior Colliculi/physiology , Visual Cortex/physiology , Animals , Female , GABA-A Receptor Agonists/pharmacology , Male , Mice, Inbred C57BL , Mice, Transgenic , Muscimol/pharmacology , Optogenetics , Photic Stimulation , Visual Pathways/drug effects , Visual Pathways/physiology
19.
Neuroimmunomodulation ; 25(2): 96-102, 2018.
Article in English | MEDLINE | ID: mdl-30110698

ABSTRACT

OBJECTIVE: Interleukin 4 (IL-4) is an anti-inflammatory cytokine related to different aspects of central nervous system development such as survival, proliferation, and differentiation, among others. Our goals were to investigate the effect of intravitreous treatment with IL-4 on the activation of downstream signaling pathways in the retina and the distribution of retinal axons within the superior colliculus (SC). MATERIAL AND METHODS: Lister hooded rats were submitted to an intravitreous injection of either IL-4 (5 U/µL) or PBS (vehicle) at postnatal day 10 (PND10). At PND11 or PND14, retinas were processed for Western blot or immunohistochemistry. At PND13, a group of animals received an intraocular injection of an anterograde tracer in the left (untreated) eye in order to label the uncrossed retinotectal axons. RESULTS: Our data revealed that intravitreous treatment with IL-4 at PND10 leads to a decrease in GFAP content and a sustained increase in the phosphorylation of STAT6 and ERK levels in the retina. IL-4 also increases retinal axonal arbors within the SC, compared to control groups. CONCLUSIONS: These data suggest that a single in vivo treatment with IL-4 during the early stages of development modulates signaling pathways in the retina, resulting in altered binocular subcortical visual connectivity.


Subject(s)
Interleukin-4/administration & dosage , MAP Kinase Signaling System/physiology , Nerve Net/metabolism , Retina/metabolism , STAT6 Transcription Factor/metabolism , Visual Pathways/metabolism , Animals , Intravitreal Injections , MAP Kinase Signaling System/drug effects , Nerve Net/drug effects , Phosphorylation/drug effects , Phosphorylation/physiology , Rats , Retina/drug effects , Rodentia , Visual Pathways/drug effects
20.
Neuroscience ; 384: 131-138, 2018 08 01.
Article in English | MEDLINE | ID: mdl-29859977

ABSTRACT

In the visual cortex, sensory deprivation causes global augmentation of the amplitude of AMPA receptor-mediated miniature EPSCs in layer 2/3 pyramidal cells and enhancement of NMDA receptor-dependent long-term potentiation (LTP) in cells activated in layer 4, effects that are both rapidly reversed by light exposure. Layer 2/3 pyramidal cells receive both feedforward input from layer 4 and intra-cortical lateral input from the same layer, LTP is mainly induced by the former input. Whether feedforward excitatory synaptic strength is affected by visual deprivation and light exposure, how this synaptic strength correlates with the magnitude of LTP in this pathway, and the underlying mechanism have not been explored. Here, we showed that in juvenile mice, both dark rearing and dark exposure reduced the feedforward excitatory synaptic strength, and the effects can be reversed completely by 10-12 h and 6-8 h light exposure, respectively. However, inhibition of NMDA receptors by CPP or mGluR5 by MPEP, prevented the effect of light exposure on the mice reared in the dark from birth, while only inhibition of NMDAR prevented the effect of light exposure on dark-exposed mice. These results suggested that the activation of both NMDAR and mGluR5 are essential in the light exposure reversal of feedforward excitatory synaptic strength in the dark reared mice from birth; while in the dark exposed mice, only activation of NMDAR is required.


Subject(s)
Dark Adaptation/physiology , Long-Term Potentiation/drug effects , Receptor, Metabotropic Glutamate 5/antagonists & inhibitors , Receptors, N-Methyl-D-Aspartate/antagonists & inhibitors , Vision, Binocular/physiology , Visual Cortex/drug effects , Visual Pathways/drug effects , Animals , Dark Adaptation/drug effects , Excitatory Amino Acid Antagonists/pharmacology , Excitatory Postsynaptic Potentials/drug effects , Excitatory Postsynaptic Potentials/physiology , Long-Term Potentiation/physiology , Mice , Pyridines/pharmacology , Visual Cortex/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL